Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 6,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,838 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · derivative · entry 24 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,838 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · derivative · entry 23 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,838 Underlying: Common Stock · 3,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $413.33 | $0.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · derivative · entry 22 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,838 Underlying: Common Stock · 3,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $604.49 | $120,898.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 21 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 8, 2020 at prices ranging from $604.40 to $604.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 525 | $603.82 | $317,005.50 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 20 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,843 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 525 shares of Company stock on June 8, 2020 at prices ranging from $603.25 to $604.22. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,196 | $602.70 | $720,829.20 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 19 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 1,196 shares of Company stock on June 8, 2020 at prices ranging from $602.15 to $603.00. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $601.29 | $240,516.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 18 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,564 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on June 8, 2020 at prices ranging from $600.85 to $601.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $600.12 | $120,024.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 17 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,964 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 8, 2020 at prices ranging from $599.66 to $600.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $598.07 | $119,614.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 16 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,164 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 771 | $597.51 | $460,680.21 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 15 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,364 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 771 shares of Company stock on June 8, 2020 at prices ranging from $597.04 to $597.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,111 | $596.47 | $662,678.17 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 14 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,135 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 1,111 shares of Company stock on June 8, 2020 at prices ranging from $595.91 to $596.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 700 | $595.31 | $416,717.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 13 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,246 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 700 shares of Company stock on June 8, 2020 at prices ranging from $594.86 to $595.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 60 | $592.46 | $35,547.60 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 12 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,946 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $590.47 | $59,047.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 11 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,006 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $589.87 | $117,974.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 10 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,106 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 8, 2020 at prices ranging from $589.41 to $590.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,200 | $587.88 | $1,881,216.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 9 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,306 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 3,200 shares of Company stock on June 8, 2020 at prices ranging from $587.88 to $587.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $587.20 | $176,160.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 8 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,506 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on June 8, 2020 at prices ranging from $586.80 to $587.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $585.58 | $117,116.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 7 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,806 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 8, 2020 at prices ranging from $585.75 to $585.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,175 | $583.67 | $685,812.25 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,006 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 1,175 shares of Company stock on June 8, 2020 at prices ranging from $583.15 to $584.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $582.31 | $116,462.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,181 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 8, 2020 at prices ranging from $581.98 to $582.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 8, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $580.65 | $58,065.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,381 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,838 | $413.33 | $1,999,690.54 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $413.33 | $1,239,990.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $413.33 | $1,239,990.00 |
DisclosureSEC source: 0001237899-20-000023 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $578.94 | $578,940.00 |
DisclosureSEC source: 0001708138-20-000064 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,643 Read SEC document |
| May 06, 2020 Filed May 6, 2020 20:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $560.00 | $1,120,000.00 |
DisclosureSEC source: 0001237899-20-000017 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,643 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · derivative · entry 11 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $482.82 | $144,846.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 10 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on March 9, 2020 at prices ranging from $482.51 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $479.21 | $239,605.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 9 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,943 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on March 9, 2020 at prices ranging from $479.05 to $479.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $476.16 | $95,232.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 8 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,443 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on March 9, 2020 at prices ranging from $476.15 to $476.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 327 | $475.31 | $155,426.37 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 7 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 327 shares of Company stock on March 9, 2020 at prices ranging from $475.19 to $475.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 9, 2020 at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 73 | $474.88 | $34,666.24 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,970 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $471.34 | $47,134.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,043 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $470.83 | $94,166.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,143 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $469.80 | $46,980.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $468.14 | $93,628.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,443 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $33.42 | $66,840.00 |
DisclosureSEC source: 0001237899-20-000014 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 21:45 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $382.83 | $382,830.00 |
DisclosureSEC source: 0001237899-20-000007 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 F1 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 7, 2020 at prices ranging from $382.79 to $382.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2020 at each separate price. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001237899-20-000003 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000003 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,643 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-19-000027 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 1,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $370.00 | $370,000.00 |
DisclosureSEC source: 0001237899-19-000027 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $33.42 | $33,420.00 |
DisclosureSEC source: 0001237899-19-000027 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-19-000020 · edgardoc.xml · derivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $360.00 | $360,000.00 |
DisclosureSEC source: 0001237899-19-000020 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $33.42 | $33,420.00 |
DisclosureSEC source: 0001237899-19-000020 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-19-000020 · edgardoc.xml · derivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $350.00 | $350,000.00 |
DisclosureSEC source: 0001237899-19-000020 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $33.42 | $33,420.00 |
DisclosureSEC source: 0001237899-19-000020 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $340.44 | $340,440.00 |
DisclosureSEC source: 0001237899-19-000018 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,323 F1 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on November 8, 2019 at prices ranging from $340.43 to $340.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.